Ionis制药2024年第四季度GAAP每股亏损$(0.66)优于预期$(1.10),销售额$2.27亿高于预期$1.376亿

财报速递2025-02-19
Ionis制药公司(NASDAQ:IONS)报告季度每股亏损$(0.66),优于分析师普遍预期的$(1.10),提升了40%。与去年同期每股亏损$(0.06)相比,这一数字大幅下降了1000%。公司报告季度销售额为$2.27亿,高于分析师普遍预期的$1.376亿,提升了64.97%。与去年同期的销售额$3.25亿相比,这一数字下降了30.15%。

以上内容来自Benzinga Earnings专栏,原文如下:

Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(1.10) by 40 percent. This is a 1000 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $227.00 million which beat the analyst consensus estimate of $137.60 million by 64.97 percent. This is a 30.15 percent decrease over sales of $325.00 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法